IDEAS home Printed from https://ideas.repec.org/a/gam/jmathe/v11y2023i2p358-d1030743.html
   My bibliography  Save this article

Testing Doses and Treatment Timelines of Anti-Angiogenic Drug Bevacizumab Numerically as a Single-Agent for the Treatment of Ovarian Cancer

Author

Listed:
  • Dharma Raj Khatiwada

    (School of STEM, College of Agriculture, Community and the Sciences, Kentucky State University, 400 E Main St, Frankfort, KY 40601, USA)

  • Miana Wallace

    (School of STEM, College of Agriculture, Community and the Sciences, Kentucky State University, 400 E Main St, Frankfort, KY 40601, USA)

Abstract

An anti-angiogenic drug in cancer treatment prevents the growth of new blood vessels in tumors by binding to VEGF molecules, which otherwise induce endothelial cells inside blood vessels to sprout the blood supply toward the tumor. This would prevent the growth of new blood cells which will deprive the tumor of nutrients, thus decreasing its carrying capacity, and ultimately shrinking its volume. With new vascularization absent, the tumor will be isolated, making it easier to treat. Although there is an availability of various anti-angiogenic drugs, their effectiveness is low compared to other cancer treatments. We are specifically pinpointing the various combination of doses and the treatment timelines as reasonable factors to increase the effectiveness of the anti-angiogenic drug Bevacizumab, which can possibly prolong the patient’s survival rate and offer lower toxicity compared to other treatment modalities such as radiotherapy and chemotherapy. We have numerically analyzed different doses of Bevacizumab, including 15 mg/kg, an FDA-approved dose if offered in conjunction with chemotherapy drugs, carboplatin and paclitaxel, as a single-agent treatment option. Based on the results, the tumor volume was observed to be stabilizing for the duration of the treatment, which was chosen to be 400 days. The toxicity levels of these doses with Bevacizumab as a single-agent treatment option have not been tested in a clinical setting. However, these mathematically promising results can provide a gateway for the successful treatment of ovarian cancer in the future.

Suggested Citation

  • Dharma Raj Khatiwada & Miana Wallace, 2023. "Testing Doses and Treatment Timelines of Anti-Angiogenic Drug Bevacizumab Numerically as a Single-Agent for the Treatment of Ovarian Cancer," Mathematics, MDPI, vol. 11(2), pages 1-6, January.
  • Handle: RePEc:gam:jmathe:v:11:y:2023:i:2:p:358-:d:1030743
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/2227-7390/11/2/358/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/2227-7390/11/2/358/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Jan Poleszczuk & Philip Hahnfeldt & Heiko Enderling, 2015. "Therapeutic Implications from Sensitivity Analysis of Tumor Angiogenesis Models," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-10, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dávid Csercsik & Levente Kovács, 2019. "Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab," Complexity, Hindawi, vol. 2019, pages 1-18, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jmathe:v:11:y:2023:i:2:p:358-:d:1030743. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.